US FDA backs down on 'burdensome' proposal in 'dear healthcare provider letter'
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has removed a controversial proposal in the draft guideline it is finalizing on when and how drug companies should write a "dear health care provider (DHCP) letter" to communicate important safety information about marketed products to physicians and others responsible for patient care1.
You may also be interested in...
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.